Latest Health News

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.

Ecofibre Limited reports a mixed financial performance for Q2 2025, highlighting significant debt reduction efforts and strategic restructuring to return to positive cash flows.

Hartshead Resources reports a robust December quarter with strategic progress on UK gas developments, fiscal clarity from government levy changes, and the acquisition of new licenses boosting its resource base.

Eden Innovations Ltd reports a striking 158% increase in US OptiBlend® sales for Q2 FY25, alongside expanding international traction for its EdenCrete® products and strategic property sales aimed at debt reduction.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

ResMed Inc. has announced a quarterly ordinary dividend of USD 0.053 per share for holders of its ASX-listed Chess Depositary Instruments, with payments scheduled for March 2025.

Elixinol Wellness delivered a standout Q4 FY24 performance with a 71% jump in cash receipts and a 64% rise in revenue, driven by key acquisitions and operational efficiencies. The company edges closer to EBITDA break-even, setting the stage for growth in 2025.

LiveHire’s 2Q25 report reveals a sharp rise in operating cash outflows and a dip in SaaS revenue, offset by strong growth in its North American Direct Sourcing business and a strategic capital raise amid an ongoing takeover.

Winsome Resources has filed a key Technical Report for its Adina Lithium Project and extended payment terms for the Renard Operation acquisition, marking significant progress in project development and regulatory engagement.

Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.

BetMakers Technology Group reports a sharp 69% reduction in adjusted EBITDA loss and a 43% improvement in operating cash flow for Q2 FY25, marking a pivotal shift from restructuring to growth. The company’s successful Apollo platform migration and cost-cutting initiatives underpin a confident outlook for revenue expansion.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.